Trial of Deferiprone in Parkinson’s Disease

J 2022

Trial of Deferiprone in Parkinson’s Disease

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL et. al.

Basic information

Original name

Trial of Deferiprone in Parkinson’s Disease

Authors

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK and B. POST

Edition

The New England Journal of medicine, USA, Massachusetts Medical Society, 2022, 1533-4406

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

FAIRPARK II

Impact factor

Impact factor: 158.500

RIV identification code

RIV/00216224:14110/22:00127673

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1056/NEJMoa2209254

UT WoS

000898926800010

Keywords (in Czech)

Parkinsonova choroba ;neurodegenerativní porucha ;FAIRPAK II ;klinické hodnocení

Keywords in English

Parkinson’s Disease ;neurodegenerative disorder ;FAIRPAK II ;clinical trial

Abstract

V originále

BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK and B. POST. Trial of Deferiprone in Parkinson’s Disease. The New England Journal of medicine. USA: Massachusetts Medical Society, 2022, vol. 387, NA, p. 2045-2055. ISSN 1533-4406. Available from: https://dx.doi.org/10.1056/NEJMoa2209254.

@article{2243480,
   author = {DEVOS, D. and LABREUCHE, J. and RASCOL, O. and CORVOL, J.andC. and DUHAMEL, A. and DELANNOY, P. Guyon and POEWE, W. and COMPTA, Y. and PAVESE, N. and RŮŽIČKA, E. and DUŠEK, P. and POST, B.},
   article_location = {USA},
   article_number = {NA},
   doi = {http://dx.doi.org/10.1056/NEJMoa2209254},
   keywords = {Parkinson’s Disease ;neurodegenerative disorder ;FAIRPAK II ;clinical trial},
   language = {eng},
   issn = {1533-4406},
   journal = {The New England Journal of medicine},
   title = {Trial of Deferiprone in Parkinson’s Disease},
   url = {https://www.nejm.org/doi/full/10.1056/NEJMoa2209254},
   volume = {387},
   year = {2022}
}

TY  - JOUR
ID  - 2243480
AU  - DEVOS, D. - LABREUCHE, J. - RASCOL, O. - CORVOL, J.-C. - DUHAMEL, A. - DELANNOY, P. Guyon - POEWE, W. - COMPTA, Y. - PAVESE, N. - RŮŽIČKA, E. - DUŠEK, P. - POST, B.
PY  - 2022
TI  - Trial of Deferiprone in Parkinson’s Disease
JF  - The New England Journal of medicine
VL  - 387
IS  - NA
SP  - 2045-2055
EP  - 2045-2055
PB  - Massachusetts Medical Society
SN  - 15334406
KW  - Parkinson’s Disease ;neurodegenerative disorder ;FAIRPAK II ;clinical trial
UR  - https://www.nejm.org/doi/full/10.1056/NEJMoa2209254
N2  - BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
ER  -

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK and B. POST. Trial of Deferiprone in Parkinson’s Disease. \textit{The New England Journal of medicine}. USA: Massachusetts Medical Society, 2022, vol.~387, NA, p.~2045-2055. ISSN~1533-4406. Available from: https://dx.doi.org/10.1056/NEJMoa2209254.

Detailed Information on Publication Record